Cantor Maintains Hold On Cubist Pharmaceuticals Following 3Q14 Earnings
In a research report issued today, Cantor analyst Irina Rivkind maintained a Hold rating on Cubist Pharmaceuticals (NASDAQ:CBST) with a $64 price target, despite strong third-quarter results.
Rivkind noted, “We reiterate our HOLD rating and $64 PT, which is based on an evenly weighted blend of DCF and takeout valuation.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Irina Rivkind Koffler has a total average return of 13.6% and a 59.7% success rate. Rivkind Koffler has a -18.9% average return when recommending CBST, and is ranked #182 out of 3337 analysts.